Approved a new initial treatment for advanced non-small-cell lung cancer after clinical trials showed patients lived longer without disease progression, compared to the standard treatment currently used. The chemotherapy-free combination involves two drugs, one of which has never been approved for use in the U.S. called lazertinib, which will be...

FDA Approves New Treatment for Non-Small-Cell Lung Cancer

GSK plc (. GSK - Free Report) announced that the FDA has granted a Breakthrough Therapy Designation to its investigational B7-H3-targeted antibody-drug conjugate (ADC), GSK5764227 (GSK’227), for the treatment of relapsed/refractory extensive-stage small-cell lung cancer (ES-SCLC). The FDA grants Breakthrough Therapy designation to expedite the development and review of...

GSK's ADC Drug for Lung Cancer Gets FDA's Breakthrough Tag

Illumina has secured an FDA approval to bring its pan-cancer tissue profiling test to U.S. shores. A version of the company’s TruSight Oncology Comprehensive genomic diagnostic kit has been available in Europe since 2022. The test screens solid tumor samples for 517 different genes to uncover useful biomarker patterns that can identify patients who may benefit from specific immunotherapies.

FDA approves Illumina's tumor biomarker test as a pan-cancer companion diagnostic

The decision follows phase 3 EV-302 trial findings showing improved survival with enfortumab vedotin plus pembrolizumab vs chemotherapy in urothelial cancer. The European Commission (EC) has granted marketing authorization for the use of enfortumab vedotin-ejfv (Pedcev) plus pembrolizumab (Keytruda) as a first-line treatment in patients with unresectable or metastatic urothelial cancer eligible for platinum-based chemotherapy, according to a press release from the drug’s developer, Astellas Pharma Inc.1.

Enfortumab Vedotin Combo Gains European Approval for Urothelial Cancer

Lung cancer can cause diarrhea, but this is rarely due to the condition itself. It is more commonly the result of side effects from cancer treatment. Lung cancer can result in gastrointestinal symptoms like diarrhea. This is because the condition can. and make you more susceptible to infection. However, this...

Can Lung Cancer Cause Diarrhea?

When lung cancer spreads beyond the lungs, it usually first affects nearby lymph nodes. But doctors don’t usually consider lung cancer to be “metastatic” until it has spread to more distant parts of the body. Lung cancer can spread throughout the body in several ways. Cancerous cells...

Where Lung Cancer Spreads First

Cancer Health

In 2006, Diana Lindsay, who had never so much as held a cigarette, was diagnosed with stage 4 lung cancer. It had metastasized to both lungs, her brain and lymph nodes. Keith Eaton, MD, PhD, clinical director of thoracic, head and neck medical oncology at Fred Hutch Cancer Center, told her that a typical patient in this situation would have about nine months to live. But he also observed that she seemed remarkably strong and vital. “He said, ‘You don’t look like my normal lung cancer patient,’” said Lindsay, who had just returned from a business trip to Europe. She was 54 at the time. “He didn’t want to take away the health I had for the limited time I had to live.”

20 Years Since an EGFR Discovery, a Woman With Stage IV Lung Cancer Is Thriving

Amherst, MA

Innovative research has led to a new treatment for pancreatic cancer that utilizes nanoparticles to stimulate immune responses and improve drug delivery. This strategy has produced significant results, with eight out of nine mice showing tumor improvements and two seeing their tumors completely eradicated. This approach holds promise for broader applications in oncology.

New Nanoparticle Cancer Treatment Successfully Shrinks and Eliminates Pancreatic Tumors

Small cell lung cancer (SCLC) is a fast-growing cancer that develops in cells within the lung. A range of medical tests and procedures are available to help doctors diagnose SCLC and create an appropriate treatment plan. Lung cancer is a complex disease comprising various subtypes. A person who receives a...

How do doctors diagnose small cell lung cancer?

Exposure to radiation during lung cancer treatment may increase future arrhythmia risk. Arrhythmia subtype varied by radiation dose and exposed cardiac structure. Exposure of certain cardiac structures to radiation during treatment of surgically inoperable or unresectable non-small cell lung cancer was associated with increased arrhythmia risk, researchers reported. The researchers...

Lung cancer radiotherapy exposes patients to arrhythmia risks based on factors such as dose

Toni English’s medical team was giddy. It was six weeks after English had completed an experimental cancer treatment, and she had arrived at the Orlando Health Cancer Institute in Florida with her husband to see the results of her latest scan. Her team gathered in a patient exam room...

A newly approved ‘living drug’ could save more cancer patients’ lives

Seattle, WA

Lawrence Fong, MD’s research has focused on immunotherapy for more than 30 years. For many of those years, the new scientific director of the Immunotherapy Integrated Research Center at Fred Hutch Cancer Center considered immunotherapy — the practice of harnessing the body’s own immune system to fight cancer and other diseases — an idea whose time had not yet come.

How Immunotherapy Has Transformed Oncology

The MACI Arthro can be administered through small incisions using custom instruments to repair cartilage defects in the knee. The FDA has approved Vericel Corporation’s MACI for repairing cartilage defects in the knee. According to the company, MACI uses a patient’s own cells cultured on a porcine collagen membrane. This method, also known as MACI Arthro, can be administered through small incisions using custom instruments, providing a substantial improvement in full-thickness cartilage defects up to 4 cm² in size, offering a less invasive option, according to the company.1.

FDA Approves Arthroscopic Delivery of Vericel’s MACI for Knee Cartilage Defects

Genome Medicine volume 16, Article number: 107 (2024) Cite this article. Poly (ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitors (PARPi) are targeted therapies approved for homologous recombination repair (HRR)-deficient breast, ovarian, pancreatic, and prostate cancers. Since inhibition of PARP1 is sufficient to cause synthetic lethality in tumors with homologous recombination deficiency (HRD), PARP1 selective inhibitors such as saruparib (AZD5305) are being developed. It is expected that selective PARP1 inhibition leads to a safer profile that facilitates its combination with other DNA damage repair inhibitors. Here, we aimed to characterize the antitumor activity of AZD5305 in patient-derived preclinical models compared to the first-generation PARP1/2 inhibitor olaparib and to identify mechanisms of resistance.

The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models

IMU-838 daily doses of 30-mg and 45-mg suppressed the development of gadolinium-enhancing lesions by 78% and 74% compared with the placebo at 24 weeks in relapsing-remitting multiple sclerosis. New data from the phase 2 EMPhASIS trial (NCT03846219) published in Neurology Neuroimmunology & Neuroinflammation showed that vidofludimus calcium formulation (IMU-838) given...

IMU-838 Shows Reduction of Brain Lesions in Phase 2 EMPhASIS Trial for Relapsing-Remitting Multiple Sclerosis

Thyroid lymphoma is an extremely rare but highly treatable cancer that affects the thyroid gland. It can cause a mass in the neck, difficulty swallowing, and shortness of breath. Most cases of thyroid cancer start when thyroid gland cells become cancerous. Thyroid lymphoma, meanwhile, is a disease that happens when...

What to Know About Thyroid Lymphoma

Treatment with Yescarta for B-cell lymphoma may be promising within the first five years, but the risk of secondary cancers may reduce survival long term. Short-term outcomes following treatment with Yescarta (axicabtagene ciloleucel) for patients with B-cell lymphoma are reported to be promising, but long-term data regarding survivorship is still commonly unknown.

Secondary Cancers May Reduce Long-Term Survival After Yescarta in Lymphoma

Florida State

Contributors represent independent, third-party users who have joined our contributor program and self-verified their accounts. They have also demonstrated their experience writing hard news for other outlets. Contributors are expected, like all users, to adhere to our Community Standards.

contributor

Jacksonville, FL

Jacksonville Today

Jacksonville Sheriff T.K. Waters said he will consider more DUI patrols if voters legalize recreational marijuana use in Florida. Voters will consider Amendment 3 in November. It would allow adults 21 or older to possess, purchase or use marijuana products and marijuana accessories for non-medical purposes.

More DUI patrols possible if marijuana issue passes

BMC Psychiatry volume 24, Article number: 578 (2024) Cite this article. Depression is prevalent among lung cancer patients undergoing chemotherapy, and the symptom cluster of fatigue-pain-insomnia may influence their depression. Identifying characteristics of patients with different depression trajectories can aid in developing more targeted interventions. This study aimed to identify the trajectories of depression and the fatigue-pain-insomnia symptom cluster, and to explore the predictive factors associated with the categories of depression trajectories.

Trajectories of depression and predictors in lung cancer patients undergoing chemotherapy: growth mixture model

NXP800 was granted orphan drug designation by the FDA for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers. The novel GCN2 kinase activator NXP800 received orphan drug designation from the FDA for the treatment of AT-rich interactive domain-containing protein 1a (ARID1a) ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers, according to a news release from Nuvectis Pharma, Inc.1.

FDA Grants Orphan Drug Designation to NXP800 for ARID1a-Deficient Ovarian Cancers

NewsBreak

FDA Approves AstraZeneca’s Imfinzi for Lung Cancer Treatment

FDA’s latest approval of Imfinzi (durvalumab) in combination with chemotherapy for treating resectable non-small cell lung cancer before and after surgery is based on Phase III...

FDA Approves AstraZeneca’s Imfinzi for Lung Cancer Treatment

Comments / 0